Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Raw Materials (2019 - 2025)

IGC Pharma (IGC) has disclosed Raw Materials for 7 consecutive years, with $446000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Raw Materials fell 59.6% to $446000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $446000.0, a 59.6% decrease, with the full-year FY2025 number at $1.1 million, changed 0.45% from a year prior.
  • Raw Materials was $446000.0 for Q3 2025 at IGC Pharma, down from $1.1 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $3.0 million in Q4 2022 to a low of $446000.0 in Q3 2025.
  • A 5-year average of $1.8 million and a median of $2.1 million in 2023 define the central range for Raw Materials.
  • Peak YoY movement for Raw Materials: surged 910.57% in 2021, then tumbled 59.6% in 2025.
  • IGC Pharma's Raw Materials stood at $2.3 million in 2021, then soared by 30.5% to $3.0 million in 2022, then tumbled by 53.52% to $1.4 million in 2023, then dropped by 24.4% to $1.1 million in 2024, then tumbled by 58.28% to $446000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Raw Materials are $446000.0 (Q3 2025), $1.1 million (Q2 2025), and $1.1 million (Q1 2025).